CONFERENCE UPDATES: WCLC 2021

Combination of durvalumab, tremelimumab and chemotherapy as a potential new first-line mNSCLC treatment option



References
  1. Melissa L et al. Durvalumab ±Tremelimumab + Chemotherapy as First-Line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study. Presented at IASLC 2021 World Conference on Lung Cancer; September 8-14, 2021.
PROGRAMMED DEATH PROTEIN 1
MNSCLC
POSEIDON
NON-SMALL CELL LUNG CANCER
mNSCLC
Related Articles